MLTX

MoonLake Immunotherapeutics

Fundamental data last updated:November 1, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

CH

Next Earnings Date

Pending Announcement

Business Summary

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.

 


Analyze MLTX on TradingView

VALUATION

P/E

-5.18

Market Cap ($M USD)

$1.38B

Forward P/E

8.95

PEG

0.06

PRICE TO SALES

0.00

PRICE TO BOOK

5.24

EV / EBITDA

-4.73

5-Year Average P/E

Free Cash Flow Yield

-16.30%

DCF Value

$4.08

Graham Number

N/A

Price to FCF

-6.13

EV to FCF

-5.25

Earnings Yield

-19.31%

FCF Yield

-16.30%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$3.61

Next Year EPS Growth Estimate

$2.09

Next Year Revenue Growth Estimate

$817.46M

Return on Equity (ROE)

-85.61%

FREE CASH FLOW

Operating Margin

0.00%

Debt-to-Equity

0.25

Piotroski F-Score

1

Altman Z-Score

2.67

Return on Invested Capital (ROIC)

-75.47%

Current Ratio

8.60

Quick Ratio

8.60

Net Debt to EBITDA

0.79

Interest Coverage

-28.15

Gross Profit margin

0.00%

FCF PER SHARE

$-3.14

REVENUE PER SHARE

$0.00

Analyze MLTX on TradingView

Gainseekers Quantitative Analysis

Summary

MoonLake Immunotherapeutics presents a perplexing valuation scenario. Despite a Forward P/E of 8.30 suggesting potential growth, the stock’s market price has historically traded well below its DCF value, indicating possible undervaluation. However, the negative Earnings Yield and a Price to FCF ratio of -6.34 highlight significant profitability concerns. The Altman Z-score of 4.02 suggests financial stability, yet the negative ROIC and EPS reflect poor operational efficiency. This mixed bag of metrics suggests the market may be mispricing the stock, but caution is warranted given its financial health.

AI Exposure / Tech Reliance

Operating in the biotechnology sector, MoonLake Immunotherapeutics is well-positioned to leverage AI advancements in drug discovery and personalized medicine. The industry's rapid innovation cycle demands adaptability, and companies like MoonLake can benefit from AI-driven efficiencies. However, the pace of technological change also requires continuous investment and strategic foresight.

The Bull Case

For the value or GARP investor, MoonLake offers intriguing potential. Its Forward PEG ratio of 0.05 indicates significant growth at a reasonable price, a rare find in the biotech space. Despite a low Piotroski F-Score of 1, the company's robust Current Ratio of 9.27 suggests strong liquidity, providing a cushion for future investments. The low Debt/Equity ratio of 0.25 further underscores financial prudence, making it an attractive proposition for those betting on a turnaround.

The Bear Case

MoonLake's structural weaknesses are glaring. The negative ROIC of -64.61% and a Price/Book ratio of 3.61 signal inefficiencies and overvaluation. Its inability to generate positive cash flow, as evidenced by a negative FCF Yield and an EV to FCF of -5.02, raises red flags about its operational viability. The stock's technical position, with a significant distance from its 52-week high, suggests it may be overextended, posing a risk for investors seeking immediate returns.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$28.50

Institutional Ownership %

1-Year Beta

1.01

Insider Buying % (6 Mo)

Distance to 52-Week High

235.92%

Distance to 52-Week Low

68.15%

EARNINGS SURPRISE %

-7.69%

50-DAY SMA

$17.51

200-DAY SMA

$21.55

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.